Moxifloxacine Double-E Pharma

Moxifloxacin, the active ingredient in Moxifloxacine Double-E Pharma, is a fluoroquinolone presented as an oral tablet for systemic use. It treats a range of serious bacterial infections in adult patients. GNH USA supplies Moxifloxacine Double-E Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxifloxacine Double-E Pharma, a fluoroquinolone antibacterial, is indicated for several bacterial infections. - Community‑acquired bacterial pneumonia: eradicates the causative pathogens and improves respiratory function. - Acute bacterial sinusitis: clears sinus infection and relieves congestion. - Acute bacterial exacerbation of chronic bronchitis: reduces bacterial load and eases bronchial inflammation. - Skin and skin structure infections: eliminates skin‑associated bacteria and promotes healing. - Complicated intra‑abdominal infections: provides broad‑spectrum coverage for mixed bacterial flora.

Moxifloxacine Double-E Pharma may cause adverse reactions.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, usually self‑limiting. - Headache: transient cranial discomfort. - Rash: mild skin erythema or itching.

Serious or Rare Side Effects: - Tendon rupture: sudden tendon pain or swelling, especially in the Achilles. - QT interval prolongation: risk of cardiac arrhythmias, monitor ECG in susceptible patients. - Severe allergic reactions: anaphylaxis, angioedema, or bronchospasm requiring immediate medical attention.

Before prescribing Moxifloxacine Double-E Pharma, clinicians should consider several safety measures. - Assess renal function: adjust therapy in patients with significant impairment. - Monitor for tendon pain: discontinue if signs of tendonitis or rupture appear. - Check cardiac status: avoid in patients with known prolonged QT or electrolyte disturbances. - Avoid use in pregnancy: insufficient data on fetal safety; consider alternatives. - Store at room temperature below 25°C: keep in the original pack, protect from moisture.

Moxifloxacine Double-E Pharma can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: markedly reduce moxifloxacin absorption. - Systemic corticosteroids: heightened risk of tendon rupture. - Warfarin: potentiates anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - CYP450 inducers (e.g., rifampicin): may lower plasma concentrations of moxifloxacin. - Theophylline: can raise serum theophylline levels, risking toxicity. - Sulfonylurea antidiabetic agents: may require dose adjustment due to enhanced hypoglycemic effect.